Cicoxil

Quick links to important sections

Cicoxil

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cicoxil

Quick Facts

Property Description
Active ingredient Warfarin Sodium
Form Oral Tablets, Lyophilized Powder for Injection
Pharmacological class Anticoagulant, Vitamin K Antagonist (VKA)
Common use Prevention and treatment of blood clots
Origin Synthetic, Small Molecule Drug

What is Cicoxil and What Class Does it Belong To?

Cicoxil is a prescription-only pharmaceutical preparation utilizing the synthetic small molecule drug Warfarin Sodium as its active component. Structurally, it is classified as a Coumarin Derivative and belongs to the pharmacological class of Anticoagulants. It functions as a Vitamin K Antagonist (VKA), exerting a systemic effect on the body's clotting cascade. The active compound in Cicoxil is a racemic mixture of R- and S-enantiomers, a chemical feature that influences its biological activity.

Compositional Type and Available Forms

Cicoxil is primarily prepared and administered as oral tablets, which are formulated for chronic outpatient management. However, the active compound is also supplied as a sterile lyophilized powder intended for reconstitution into an injectable solution, which provides an alternative for intravenous administration. Warfarin Sodium maintains stability and bioavailability in both of these preparation formats.

General Purpose: Why is Cicoxil Used?

The general purpose of Cicoxil is the prophylaxis and treatment of the formation and expansion of thrombotic events. This is achieved by reducing the blood's overall clotting capability through interference with the liver's synthesis of four key coagulation factors. Warfarin serves a role in preventing the formation of blood clots, such as those associated with conditions like atrial fibrillation. The medication is used to maintain continuous blood flow and mitigate risks associated with vessel obstruction.

What side effects are possible with Cicoxil?

Possible side effects and safety information

The official safety profile for Warfarin Sodium (Cicoxil) is centered on the primary risk of hemorrhage (bleeding), which is classified across the frequency spectrum as the most significant and defining adverse reaction. Regulatory documentation classifies minor bleeding events as very common, while major bleeding, including fatal hemorrhage, is categorized as common. These effects are primarily addressed under Blood and Lymphatic System Disorders.

Adverse reactions are also documented within other System-Organ Classes, including Skin and Subcutaneous Tissue Disorders (e.g., skin necrosis, rash, hair loss) and Hepatobiliary Disorders (e.g., elevated liver enzymes, jaundice).

Serious Adverse Reactions and Population-Specific Safety

The label explicitly identifies rare but serious adverse reactions, such as Warfarin-induced skin necrosis and calciphylaxis, which are noted for their clinical severity. The risk of bleeding is noted to be highest during the initial period of treatment, a time-related pattern documented in regulatory statements.

Specific safety considerations are defined for certain patient populations. For instance, older adults are documented as having increased sensitivity to the effects of the drug, leading to a higher risk of major bleeding complications. Furthermore, Warfarin Sodium is officially classified as a known human teratogen, meaning its use during pregnancy is associated with significant fetal risks, which is listed as an absolute constraint in official prescribing information.

Safety limitations restrict the use of Cicoxil in patients with active bleeding, severe uncontrolled hypertension, or severe hepatic disease, as these conditions significantly elevate the risk of life-threatening hemorrhagic events.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for a Cicoxil (Warfarin Sodium) overdose is defined by its primary consequence: exaggerated anticoagulation. This condition is confirmed by a laboratory finding of an International Normalized Ratio (INR) exceeding the therapeutic range, such as an INR greater than 4.0. The clinical presentation of overdose is hemorrhage, which can be nonfatal, major, or life-threatening.

Documented manifestations of bleeding, as listed in official labeling, include unusual bruising, nosebleeds, bleeding from the gums, blood in the urine (hematuria), or bloody or tarry stools (melena). Overdose can result in severe outcomes, including fatal bleeding or acute kidney injury.

Regulatory documents identify specific risk factors for major bleeding in overdose scenarios, including age sixty-five and over and the presence of renal or hepatic dysfunction.

Immediate Actions and Reversal

Immediate action is required for suspected overdose. Seek immediate medical attention for any bleeding that will not stop, or if severe symptoms such as collapse, seizure, or unresponsiveness occur. Official management procedures involve omitting the Cicoxil dose and using specific reversal agents.

These agents, mandated for use in reversal, include Vitamin K (Phytonadione), Fresh Frozen Plasma (FFP), or Prothrombin Complex Concentrate (PCC), depending on the severity of the bleeding event. Frequent INR monitoring is required throughout the management and reversal process.

Therapeutic Uses of Cicoxil

Main Indications

Cicoxil is a medication primarily prescribed for the management of chronic conditions characterized by pain and inflammation. It belongs to the class of drugs known as non-steroidal anti-inflammatory drugs (NSAIDs). Its main therapeutic applications include:

  • Osteoarthritis: Relief of symptoms associated with the degenerative breakdown of joint cartilage and underlying bone.
  • Rheumatoid Arthritis: Management of pain and swelling caused by chronic autoimmune inflammation in the joints.
  • Ankylosing Spondylitis: Treatment of inflammatory symptoms affecting the spine and large joints.

Therapeutic Benefits

The pharmacological action of Cicoxil is centered on the inhibition of specific enzymes responsible for the production of prostaglandins, which are chemicals in the body that signal pain and promote inflammation.

Pain Management

By reducing the concentration of inflammatory mediators, Cicoxil helps alleviate persistent joint pain and musculoskeletal discomfort. This reduction in pain levels can contribute to an improved quality of daily life for individuals with chronic arthritic conditions.

Reduction of Inflammation and Swelling

Cicoxil targets the physiological processes that cause tissue swelling and tenderness. Reducing joint inflammation is essential for preventing further stiffness and maintaining the structural integrity of the affected areas over time.

Improvement in Mobility

As a result of decreased pain and inflammation, patients may experience an increase in functional mobility. This includes a reduction in morning stiffness and a greater ease of movement during physical activities, supporting the maintenance of joint flexibility.

Eligibility and Restrictions for Use

Official Regulatory Eligibility for Cicoxil (Warfarin Sodium)

Eligibility Scope Regulatory Status
Populations Contraindicated Pregnancy, due to known fetal toxicity and teratogenic risk; Active bleeding (e.g., GI ulceration); recent hemorrhagic stroke; hypersensitivity to the drug; and patients with uncontrolled malignant hypertension [FDA Label, SmPC].
Restricted or Conditional Use Patients with Hepatic Dysfunction or Renal Insufficiency require use with caution and close monitoring. Patients with known Protein C or S deficiencies must be introduced to therapy without a loading dose [SmPC, NIH].
Age-Related Eligibility Adults are the approved population. Older adults (ge 65) are at a documented increased risk of hemorrhage and may require lower doses. Safety and efficacy have not been established in the pediatric population [FDA Label].
Lactation Status Permitted / Acceptable for use during breastfeeding, as minimal amounts are excreted in breast milk [NIH, SmPC].

The official eligibility profile is strictly defined by absolute contraindications and conditional restrictions. The medicine is prohibited for pregnant women and for individuals with any condition that presents an immediate, high risk of major or fatal bleeding. For populations with factors like age (ge 65) or impaired organ function, use is conditional and requires close regulatory-mandated monitoring, reflecting a necessary limitation to ensure patient safety.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Cicoxil (Warfarin Sodium) exhibits documented interaction patterns that are classified by regulatory authorities based on pharmacokinetic and pharmacodynamic effects.

Pharmacokinetic Interactions

The most common mechanism involves changes in the drug’s exposure resulting from co-administration with substances that inhibit or induce key hepatic enzymes, specifically CYP2C9, CYP1A2, and CYP3A4. Inhibitors of these enzymes, such as amiodarone and fluconazole, are documented to increase Cicoxil's exposure and anticoagulant effect. Conversely, inducers like carbamazepine and rifampin can decrease the exposure and subsequent anticoagulant effect.

Pharmacodynamic Interactions and Restrictions

Co-administration with antiplatelet agents, Nonsteroidal Anti-inflammatory Drugs (NSAIDs), or other anticoagulants presents a documented risk of an additive pharmacodynamic effect, increasing the potential for bleeding. Certain combinations are formally classified as contraindicated, including co-use with major regional or lumbar block anesthesia and in patients with malignant hypertension. Furthermore, patients with protein C or S deficiencies require a mandatory co-administration overlap with heparin upon initiation.

Interactions with Food and Supplements

Consumption of high amounts of Vitamin K-containing foods is documented to reduce the anticoagulant effect of Cicoxil. Conversely, alcohol and cranberry products may potentiate the effect. Administration timing rules also apply to enteral feedings, which must be interrupted one hour before and one hour after the Cicoxil dose to minimize potential for interaction.

Mechanism of Action

Targeting the Vitamin K Epoxide Reductase (VKORC1) Enzyme

Cicoxil acts by non-competitively inhibiting the liver enzyme Vitamin K Epoxide Reductase (VKORC1), which facilitates the regeneration of reduced Vitamin K. This enzymatic inhibition reduces the functional supply of the active form of Vitamin K ( K H2), a cofactor required for the activation of coagulation factor proteins.


Disrupting Coagulation Factor Synthesis

This mechanism directly interferes with the final step of activation (gamma-carboxylation) for four key coagulation factors: Factor II, Factor VII, Factor IX, and Factor X. By impairing this process, the liver releases biologically inactive versions of these proteins into the bloodstream, contributing to a systemic reduction in procoagulant protein function.


Establishing a Delayed Hypocoagulable State

The development of a reduced coagulable state is not immediate, as the mechanism relies on the natural clearance (half-life) of pre-existing, active clotting factors. This time-dependent process results in a sustained reduction of procoagulant activity required for generating new thrombi. Its functional scope is limited to modulating the synthesis of new factors, having no effect on the biological structure of existing vascular thrombi.

Dosage and Administration Information

How Cicoxil is Used: Official Administration Guidelines

Cicoxil (Warfarin Sodium) administration is highly individualized and guided by the patient’s International Normalized Ratio (INR) response. The dosage is not fixed but is carefully adjusted, making monitoring and adherence to the schedule essential.


Administration Scope

Category Official Instructions
Route of administration Primarily oral (tablets), with an intravenous (IV) option available for use when oral administration is impractical.
Dosing schedule Initial Dose: Usually 2 mg to 5 mg once daily, though some regimens use 10 mg daily for the first two days in healthy individuals. Maintenance Dose: Typically ranges from 2.5 mg to 10 mg once daily and is adjusted based on INR measurements.
Frequency and timing The dose must be taken once daily at the same time each day to ensure consistent effects. It may be taken with or without food.
Missed-dose rules If a dose is missed, it should be taken as soon as possible on the same day. Patients must not double the dose the following day to compensate.

Procedural Structure and Special Conditions

  • Titration: The dosage is monitored daily or on alternate days upon initiation until the INR stabilizes within the target therapeutic range. Subsequent testing is performed at regular intervals (typically 1–4 weeks).
  • Special Populations: Older adults often require a lower initiation and maintenance dose due to increased sensitivity. Patients with certain genetic factors (e.g., CYP2C9 variants) may also require reduced dosing.
  • IV Administration: The lyophilized powder form requires reconstitution prior to intravenous administration.

This procedural structure ensures that Cicoxil use is strictly individualized and dependent on frequent laboratory-guided adjustments, demanding strict adherence to the once-daily schedule.

Recent Clinical Evidence

Research evidence / Overview of Studies for Cicoxil (Warfarin)

Evidence for Preventing Stroke in Atrial Fibrillation (AF)

Warfarin was studied extensively in Randomized Controlled Trials (RCTs) and large Systematic Reviews to explore its use in adults with Atrial Fibrillation (AF), a heart rhythm condition. Research included patient groups with varying levels of risk for clotting events. The studies primarily examined outcomes related to systemic or functional imbalance, such as the occurrence of stroke and other clotting events.

Studies reported patterns related to the occurrence of thrombotic events in the observed populations when compared to control groups. These studies help show what has been observed so far regarding the measured frequency of serious clotting events; research also highlights that achieving the desired International Normalized Ratio (INR) often required careful and frequent dose adjustments due to high variability among individuals.

What remains uncertain is the optimal approach for monitoring Warfarin in the most frail or oldest adult populations, where evidence from RCTs may be less comprehensive. Furthermore, long-term outcomes for AF patients tend to rely more heavily on observational studies.


Evidence for Treating and Preventing Venous Thromboembolism (VTE)

Warfarin was evaluated in RCTs and Systematic Reviews for its application in adults who had experienced an acute Venous Thromboembolism (VTE), which includes Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE). These studies explored short-term and extended treatment plans, measuring outcomes describing episodic or acute changes like the recurrence of DVT or PE.

Studies examined and described patterns related to VTE recurrence in the observed populations. Trials documented the challenges associated with managing the drug's narrow therapeutic window and the concurrent reporting of bleeding events. The evidence is limited regarding the definitively optimal duration of extended therapy for all unprovoked VTE cases, and scientific consensus on this point is not yet fully settled.


Research on Genetic Factors and Dosing

Research examined the initiation of Warfarin therapy in short-term Prospective Randomized Trials to see if using an individual’s genetic information (e.g., CYP2C9 and VKORC1 genes) could more rapidly and accurately determine their stable dose. Some studies reported patterns related to faster dose stabilization, while other large trials reported findings were mixed, with no significant difference found. Ultimately, the clinical impact of genetic guidance on major long-term vascular events has not been fully established in all populations.

Key Studies & References Antithrombotic Management in Bioprosthetic and Mechanical Heart Valves (Professional Guidelines Review)

Frequently Asked Questions (FAQ)

Common questions about Cicoxil (FAQ)


Q: How quickly is Cicoxil expected to start working?

The full anticoagulant effect of Cicoxil is described as not being immediate. Official documentation indicates that the onset of the effect is generally delayed by several days. This time delay is related to how long it takes for pre-existing clotting factors in the blood to naturally clear from the body.

Q: Can Cicoxil be taken with over-the-counter pain relievers like Tylenol (acetaminophen)?

Regulatory documents state that co-administration with acetaminophen is a potential interaction. Taking large or chronic doses of acetaminophen may lead to an increase in the anticoagulant effect of Cicoxil.

Q: Can Cicoxil be taken with vitamins or herbal supplements?

Official guidance documents indicate that various vitamins, herbal products, and dietary supplements may interact with Cicoxil. This can happen if a supplement contains Vitamin K or affects certain liver enzymes responsible for processing the drug. Regulatory bodies recommend reviewing all supplements with a healthcare professional before use.

Q: Are there specific symptoms that mean I should stop taking Cicoxil?

Official safety information highlights specific symptoms of serious bleeding which, if observed, should be discussed with a healthcare professional. These signs can include black or bloody stools, unusual or easy bruising, or heavy or prolonged bleeding from gums or wounds.

Q: Is Cicoxil considered a high-risk medication?

According to regulatory documentation, the primary risk associated with Cicoxil is hemorrhage, or bleeding. Minor bleeding events are classified as very common. More serious major or fatal bleeding is categorized as common, indicating this is the defining adverse reaction of the medicine.

Q: What is the legal classification of Cicoxil in the US?

Cicoxil is categorized as a prescription-only pharmaceutical preparation (Rx). It is not designated as a controlled substance under federal schedules in the United States.

Q: Is it normal if I bruise easily when taking Cicoxil?

Official safety data classifies minor bleeding events as very common when using Cicoxil. Easy bruising may be consistent with this type of common, minor bleeding effect.

Q: How long does the effect of one dose of Cicoxil usually last?

Pharmacological studies indicate that the active compound in Cicoxil has a relatively long half-life. This chemical property contributes to the drug's sustained effect in the body and is why administration guidelines recommend a single dose once every 24 hours.

Q: Does Cicoxil affect birth control pills?

Regulatory documents list oral contraceptives as substances that may interact with Cicoxil. This interaction is described as potentially leading to a decrease in the medicine's anticoagulant effect.

Q: Is Cicoxil available as a generic medicine?

The active ingredient in Cicoxil, Warfarin Sodium, is a well-established compound. It is generally available as an authorized generic medication, in addition to brand-name preparations.

Q: Is it normal to feel a bit dizzy in the first few days of taking Cicoxil?

Dizziness is noted in safety documentation as an adverse reaction that has been reported during use. The official information describes it as a less frequent occurrence.

Q: Is there a risk of dependency or addiction with Cicoxil?

Official regulatory documents describe no known risk of dependency or abuse associated with the use of this medicine. Cicoxil is not classified as a scheduled drug with abuse potential.

Q: Does Cicoxil affect a person's ability to drive or operate machinery?

The official product label does not typically describe a direct effect of Cicoxil on a person's ability to drive or safely operate machinery.

Q: How does Cicoxil get eliminated from the body?

The active ingredient is primarily processed in the body by liver enzymes, specifically CYP2C9. After this metabolism occurs, the inactive components are subsequently eliminated through the urine and feces.

Q: What is the typical duration of treatment with Cicoxil?

The duration of treatment with Cicoxil is guided by the specific medical condition it is addressing. For conditions like stroke prevention in atrial fibrillation, use may be long-term, whereas treatment for a venous clot may involve a shorter, defined period.

Q: Are there any known issues with abruptly stopping Cicoxil?

Regulatory guidelines describe abrupt discontinuation of Cicoxil as something that should be avoided. Stopping the medicine suddenly can lead to a quick return of the blood's ability to clot, which may increase the risk of thrombotic events.

Q: Can Cicoxil be split or crushed?

The oral tablets are typically manufactured with a score mark. This allows them to be split when necessary to help achieve the precise, individualized dose determined by your medical response.

Q: What is the maximum allowed period of time a person can take Cicoxil?

Official regulatory documents do not specify a universal maximum period for Cicoxil use. For many chronic conditions, such as the prevention of stroke in atrial fibrillation, use may be recommended indefinitely or long-term.

Q: Is Cicoxil available in different strengths?

Yes, the oral tablets are available in multiple dosage strengths. The regulatory information indicates these strengths are often color-coded to assist with identification and the necessary precise dosing adjustments.

How should Cicoxil be stored and disposed of?

How to Store and Dispose of Cicoxil?

The storage and disposal of Cicoxil (Warfarin Sodium) must align with official regulatory requirements to maintain product stability and safety.

Requirement Category Official Instructions
Temperature & Environment Store at normal room temperature in a cool, dry place. The medicine must be kept from freezing, excess heat, and moisture.
Container & Integrity Keep the medicine in the original container and keep the container tightly closed to protect stability.
Child Safety It is mandatory to keep Cicoxil stored out of the reach of children.
Disposal Consult a healthcare professional or pharmacist on proper disposal. Unused or expired medication should be disposed of via a drug take-back program or designated collection site. Avoid release to the environment.

These conditions are set to protect the integrity of the active ingredient and ensure environmental compliance when the product is eventually discarded.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cicoxil found in:

A-Z Index: